Search results
Results from the WOW.Com Content Network
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). [4] [5] The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. [6]
In the documentary, filmmaker Liz Canner takes a job editing erotic movies for a drug trial for a pharmaceutical company called Vivus. Her employer is developing what they hope will be the first Viagra drug for women that wins FDA approval to treat a new disease: female sexual dysfunction (FSD). Liz gains permission to film the company's work ...
Flibanserin is the first pharmaceutical product from Sprout Pharmaceuticals [14] for premenopausal women with HSDD. The drug was approved by the FDA in 2015. It compiles a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist. [15] and is an antidepressant [16] that was originally developed for depression. [12]
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
A panel of U.S. Food and Drug Administration experts decided Friday that Boehringer Ingelheim's so-called "female viagra" drug, flibanserin, doesn't provide enough benefit to outweigh the risks ...
A New Drug Application of bremelanotide for female sexual dysfunction was accepted by the US Food and Drug Administration (FDA) in June 2018, with a Prescription Drug User Fee Act (PDUFA) goal date set for 23 March 2019. [30] It was approved for use in the United States in June 2019. [3] [31] [32]
The U.S. Food and Drug Administration is asking a panel of experts to weigh in on a women's version of the male sexual dysfunction drug Viagra. The FDA is considering Boehringer Ingelheim's drug ...